相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations
W. Liu et al.
LEUKEMIA (2017)
Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels
Chenbo Ding et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+Breast Cancers With ERBB Ligand Overexpression
Luis J. Schwarz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies
Raghav Sundar et al.
CANCER DISCOVERY (2017)
Investigating the utility of human melanoma cell lines as tumour models
Krista Marie Vincent et al.
ONCOTARGET (2017)
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
Sean Caenepeel et al.
Oncotarget (2017)
Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
Branka Radic-Sarikas et al.
SCIENTIFIC REPORTS (2017)
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+Breast Cancers With ERBB Ligand Overexpression
Luis J. Schwarz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Gab3 is required for human colorectal cancer cell proliferation
Shihao Xiang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface
David Bier et al.
CHEMMEDCHEM (2016)
Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression
C. Duckworth et al.
ONCOGENE (2016)
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
Daniele Oddo et al.
CANCER RESEARCH (2016)
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Sebastian Halbach et al.
CELL COMMUNICATION AND SIGNALING (2016)
Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance
Michael P. Smith et al.
CLINICAL CANCER RESEARCH (2016)
Pan-HERAn antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers
Sofie Ellebaek et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model
S. Halbach et al.
LEUKEMIA (2016)
The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)
Andrew M. Kidger et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S. Hong et al.
CANCER DISCOVERY (2016)
The kinome 'at large' in cancer
Emmy D. G. Fleuren et al.
NATURE REVIEWS CANCER (2016)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion
Dominik Noerz et al.
CELLULAR SIGNALLING (2015)
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Rona Yaeger et al.
CLINICAL CANCER RESEARCH (2015)
MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression
Rongpan Bai et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Proteinase-activated Receptor 2 Promotes Cancer Cell Migration through RNA Methylation-mediated Repression of miR-125b
Lan Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Enzo Medico et al.
NATURE COMMUNICATIONS (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
Luigi Fattore et al.
ONCOTARGET (2015)
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
Anirudh Prahallad et al.
CELL REPORTS (2015)
B-Raf Inhibitors Induce Epithelial Differentiation in BRAF-Mutant Colorectal Cancer Cells
Ricarda Herr et al.
CANCER RESEARCH (2015)
A comprehensive transcriptional portrait of human cancer cell lines
Christiaan Klijn et al.
NATURE BIOTECHNOLOGY (2015)
Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines
Melanie Boerries et al.
GENOMICS DATA (2015)
The dynamic control of signal transduction networks in cancer cells
Walter Kolch et al.
NATURE REVIEWS CANCER (2015)
Clinical Significance of GAB2, a Scaffolding/Docking Protein Acting Downstream of EGFR in Human Colorectal Cancer
Tae Matsumura et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
BRAF Mutation Predicts for Poor Outcomes After Metastasectomy in Patients With Metastatic Colorectal Cancer
Rona Yaeger et al.
CANCER (2014)
Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
Curtis H. Kugel et al.
CANCER RESEARCH (2014)
Molecular Pathways: HER3 Targeted Therapy
Kinisha Gala et al.
CLINICAL CANCER RESEARCH (2014)
Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
K. Connolly et al.
CURRENT ONCOLOGY (2014)
A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
Roland Rad et al.
CANCER CELL (2013)
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Esther Castellano et al.
CANCER CELL (2013)
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Sebastian Halbach et al.
CELL COMMUNICATION AND SIGNALING (2013)
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Muling Mao et al.
CLINICAL CANCER RESEARCH (2013)
Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma
A. Hoeben et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
F. U. Woehrle et al.
LEUKEMIA (2013)
Network quantification of EGFR signaling unveils potential for targeted combination therapy
Bertram Klinger et al.
MOLECULAR SYSTEMS BIOLOGY (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Functional characterization of cancer-associated Gab1 mutations
C. Ortiz-Padilla et al.
ONCOGENE (2013)
Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition
S. Cagnol et al.
ONCOGENE (2013)
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
A. S. Little et al.
ONCOGENE (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling
Michael Roering et al.
EMBO JOURNAL (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells
Y. Wang et al.
ONCOGENE (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer
Ben Tran et al.
CANCER (2011)
Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation
Maria Teresa Herrera Abreu et al.
MOLECULAR BIOLOGY OF THE CELL (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
Zhenfeng Zhang et al.
CARCINOGENESIS (2010)
Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development
Emmy D. G. Fleuren et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
E3 ubiquitin ligases in ErbB receptor quantity control
Kermit L. Carraway
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2010)
Gab2-Mediated Signaling Promotes Melanoma Metastasis
Basil Horst et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Function, regulation and pathological roles of the Gab/DOS docking proteins
Franziska U. Woehrle et al.
CELL COMMUNICATION AND SIGNALING (2009)
GAB2 Amplifications Refine Molecular Classification of Melanoma
Karen A. Chernoff et al.
CLINICAL CANCER RESEARCH (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
How to Grb2 a Gab
Franziska U. Woehrle et al.
STRUCTURE (2009)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis
H. L. Bennett et al.
ONCOGENE (2008)
EphB ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells
Carme Cortina et al.
NATURE GENETICS (2007)
Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein
T Brummer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A role for the scaffolding adapter GAB2 in breast cancer
M Bentires-Alj et al.
NATURE MEDICINE (2006)
EphB2 is a prognostic factor in colorectal cancer
AM Jubb et al.
CLINICAL CANCER RESEARCH (2005)
EphB receptor activity suppresses colorectal cancer progression
E Batlle et al.
NATURE (2005)
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers
C Hafner et al.
CLINICAL CHEMISTRY (2004)
Transcriptional regulation of AKT activation by E2F
M Chaussepied et al.
MOLECULAR CELL (2004)
The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer
RJ Daly et al.
ONCOGENE (2002)
PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2
DK Lynch et al.
EMBO JOURNAL (2002)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
分享论文
